GSK enters agreement to acquire 35Pharma Inc.
GSK • • general
Key Points:
- GSK has agreed to acquire 35Pharma Inc., a clinical-stage biopharmaceutical company, for $950 million in cash, gaining access to HS235, a promising activin signalling inhibitor for treating cardiopulmonary diseases including pulmonary hypertension (PH).
- HS235 has completed phase I trials and is set to enter studies for pulmonary arterial hypertension (PAH) and PH due to heart failure with preserved ejection fraction (PH-HFpEF); it offers potential benefits such as reduced bleeding risk and unique metabolic advantages over existing therapies.
- Pulmonary hypertension affects approximately 82 million people worldwide with limited treatment options and a five-year survival rate of about 50%, while the global PH therapy market is expected to reach $18 billion by
